Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lamivudine tablet composition and preparation method thereof

A lamivudine tablet and a lamivudine technology, which are applied in the field of medicine, can solve problems such as unsatisfactory disintegration effect, and achieve the effects of good taste, not easy to absorb moisture, and delicate appearance

Inactive Publication Date: 2017-10-31
南京清洛生物科技有限公司
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] However, it has been found in practice that the disintegration effect of the above preparations is not ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lamivudine tablet composition and preparation method thereof
  • Lamivudine tablet composition and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Get the raw and auxiliary materials lamivudine, microcrystalline cellulose, sodium starch glycolate, silicon dioxide, and magnesium stearate, and pass through an 80-mesh sieve. Take by weighing 100g of lamivudine, 130g of microcrystalline cellulose, 10g of sodium starch glycolate, 2g of silicon dioxide, and 2g of magnesium stearate, mix uniformly, measure the content of mixed intermediates, and calculate the tablet weight after passing the test. Direct compression. Get lamivudine tablet core, put in coating pan, carry out coating with coating solution (70% ethanol solution of hypromellose, polysorbate 80, macrogol 4000, titanium dioxide), until weight gain 2%, the coated tablets are dried and solidified to obtain finished lamivudine tablets, which are fully inspected and packaged.

Embodiment 2

[0042] Get the raw and auxiliary materials lamivudine, microcrystalline cellulose, sodium starch glycolate, silicon dioxide, and magnesium stearate, and pass through a 90-mesh sieve. Take by weighing 100g of lamivudine, 130g of microcrystalline cellulose, 10g of sodium starch glycolate, 2g of silicon dioxide, and 2g of magnesium stearate, mix uniformly, measure the content of mixed intermediates, and calculate the tablet weight after passing the test. Direct compression. Get lamivudine tablet core, put in coating pan, carry out coating with coating solution (70% ethanol solution of hypromellose, polysorbate 80, macrogol 4000, titanium dioxide), until weight gain 3%, the coated tablets are dried and solidified to obtain finished lamivudine tablets, which are fully inspected and packaged.

Embodiment 3

[0044] Get the raw and auxiliary materials lamivudine, microcrystalline cellulose, sodium starch glycolate, silicon dioxide, and magnesium stearate, and pass through a 100-mesh sieve. Take by weighing 100g of lamivudine, 130g of microcrystalline cellulose, 10g of sodium starch glycolate, 2g of silicon dioxide, and 2g of magnesium stearate, mix uniformly, measure the content of mixed intermediates, and calculate the tablet weight after passing the test. Direct compression. Get lamivudine tablet core, put in coating pan, carry out coating with coating solution (70% ethanol solution of hypromellose, polysorbate 80, macrogol 4000, titanium dioxide), until weight gain 4%, after the coated tablet is dried and solidified, the finished product of lamivudine tablet is obtained, which is obtained after full inspection and packaging.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a lamivudine tablet composition and a preparation method thereof. The core of the lamivudine tablet composition is prepared from the following ingredients: 80-120 parts of lamivudine, microcrystalline cellulose 90-150 parts, 4-20 parts of sodium starch glycolate, 1-6 parts of silicon dioxide, 0.5-4 parts of magnesium stearate. The preparation method is as follows: sieving; weighing lamivudine, microcrystalline cellulose, sodium carboxymethyl starch, silicon dioxide, and magnesium stearate, mixing evenly, measuring the content of the mixed powder, and calculating the tablet weight after passing the test. It is directly pressed into tablets, coated, dried, fully inspected and packaged to obtain the finished product.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a lamivudine tablet composition and a preparation method thereof. technical background [0002] Lamivudine is a deoxycytidine analog with the chemical name (2R,5S)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolane -5-yl)-(1H)-pyrimidin-2-one. [0003] Its molecular structural formula is as follows: [0004] [0005] Molecular formula: C 8 h 11 N 3 o 3 S [0006] Hepatitis B is an epidemic infectious disease with high morbidity, strong infectivity, and serious harm to human health. It is a global public health problem. More than 300,000 people die of hepatitis B-related complications every year in my country, and the 5-year mortality rates of chronic hepatitis B, compensated and decompensated liver cirrhosis are 0%-2%, 14%-20% and 70%- 86%. The total cost of hepatitis B treatment in China exceeds 100 billion each year. Chronic hepatitis B and its complications not only bring great dise...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/20A61K9/30A61K31/513A61K47/38A61K47/36A61K47/04A61K47/12A61K47/26A61K47/10A61P31/20A61P1/16
CPCA61K9/2054A61K9/2009A61K9/2013A61K9/2059A61K9/2813A61K9/2826A61K9/2853A61K9/2866A61K31/513
Inventor 沙薇
Owner 南京清洛生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com